In a training subset of the larger cohort, the company was able to develop classifiers that detected many cancers while minimizing false positives.
The firm has partnered with the University of Surrey to validate and potentially commercialize a test that detects mRNA biomarkers from patient urine samples.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
The two companies are entering a partnership to introduce diagnostic tests using NanoString's nCounter technology in Japan, beginning with a lymphoma assay.
Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.
The list includes "high throughput DNA sequence analyzer," "DNA genetic analyzer," and "mass spectrometer for clinical multiplex test systems."
The technologies monitor patient response to immunotherapies.
Using Luminex's FlexMap detector, the method allows quantification of cells in a mixture of up to hundreds of individual cells lines treated with drugs in vitro.
Bio-Techne is the second firm to sign an instrument distribution deal with Luminex in recent weeks and will continue to develop assays for the Luminex platform.
The sensor features a DNA-based steric hindrance method, and can detect the presence of antibodies in whole blood in less than 10 minutes.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.